K

N

Nextech Invest

Crunchbase
Pitchbook
Crunchbase

Deals on record

6

Common Fundraising Type

Series C

A
AIRNA

Biotech • RNA Editing Therapeutics

Venrock Healthcare Capital Partners logo
RTW Investments logo
Nextech Invest logo
ND Capital logo

Airna is a biotech company that specializes in RNA editing therapeutics, aiming to target diseases inaccessible through other methods, with its first program focusing on treating the inherited genetic disease alpha-1 antitrypsin deficiency (AATD).

Series B
$155M
04/01/2025
Article
B
Be Bio

Engineered B Cell Medicines • Therapeutic proteins

Nextech logo
Takeda Ventures logo
RA Capital Management logo
Longwood Fund logo

Be Biopharma is developing engineered B cell medicines to produce therapeutic proteins for treating conditions like Hemophilia B and Hypophosphatasia.

Series C
$92M
01/15/2025
Article
A
Alpha-9 Oncology

Radiopharmaceuticals • Clinical-stage

Ascenta Capital logo
Lightspeed Venture Partners logo
Samsara BioCapital logo
RA Capital Management logo

Alpha-9 Oncology Inc. develops targeted radiopharmaceuticals to improve cancer treatment.

Series C
$175M
10/23/2024
Article
C
Circle Pharma

Biopharmaceutical • Clinical development

The Column Group logo
Nextech Invest logo
Euclidean Capital logo

Circle Pharma is a biopharmaceutical company developing cell-permeable macrocycle treatments for cancer and other serious diseases.

Series D
$90M
09/03/2024
Article
A
Atavistik Bio

Biotech • Precision Allosteric Therapeutics

The Column Group logo
Nextech Invest logo
Lux Capital logo

Atavistik Bio is a biotech company developing precision allosteric therapeutics for oncology, leveraging proprietary screening technology and AI to discover new treatment sites on proteins or RNA.

Equity
$40M
12/19/2023
Article
M
Mariana Oncology

Biotechnology • Oncology

Forbion logo
Deep Track Capital logo
Surveyor Capital logo
RA Capital Management logo

Mariana Oncology is a biotechnology company that develops targeted peptide-based radiopharmaceuticals for the treatment of cancer, with a focus on delivering optimized radiation doses to solid tumors.

Series B
$175M
09/07/2023
Article